ReviewFrontiers in pharmacology2024
Different therapeutic approaches in melasma: advances and limitations.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial.Scientific reports · 2025Trial
- Comparative study of different treatment modalities for melasma: introducing a novel nanotechnology-based tranexamic acid microemulsion.Archives of dermatological research · 2025Trial
- Global consensus on the management of melanin hyperpigmentation disorders.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Innovations in Refractory Melasma: Mechanism-Based Management and Emerging Therapeutic Strategies.Cureus · 2026Review
- Efficacy and Safety of Picosecond Laser Combined With Sodium Hyaluronate for Melasma.Plastic and reconstructive surgery. Global open · 2026Article
- Innovative Nanocarriers: Elastic Aspasomes Loaded with Metformin Hydrochloride for Effective Management of Melasma: In Vitro Studies and Clinical Appraisal.Pharmaceutics · 2026Article
- Improved clinical efficacy of melasma with combination therapy of intense pulsed light and tranexamic acid: A retrospective analysis.Medicine · 2026Article
- Curcumin-loaded nanocarriers for dermatological applications: current advances and biomedical implications.EXCLI journal · 2026Review
- Clinical Effects and Safety of Radiofrequency Microneedling for the Management of Melasma: A Retrospective Study.Aesthetic surgery journal. Open forum · 2026Article
- Targeting Melasma: Innovations in Pigment Deposition and Photoaging in Cosmetic Dermatology.Journal of cosmetic dermatology · 2026Review
- A Retrospective Analysis of Radiofrequency Microneedling for Melasma Management in the Japanese Population.Clinical, cosmetic and investigational dermatology · 2026Article
- Minoxidil cyclodextrin inclusion complex-loaded microemulsions and transfersomes for androgen alopecia treatment: a comparative study.Drug delivery and translational research · 2025Article
- Article
- Decrypting the Potential of Lipidic Vesicular System for Delivery Enhancement of Tranexamic Acid in Melasma Hyperpigmentation Treatment.Advanced pharmaceutical bulletin · 2025Review
- In Vivo Evaluation of Melasma Pathologic Features and Treatment Response by 2-Photon Microscopy.JAMA dermatology · 2025Article
- The Use of Medium-Deep Peelings to Treat Melasma: A Case Series Study.Journal of cosmetic dermatology · 2025Article
- Margarita (Pearl) Extract Alleviates Melasma by Targeting CAMP-Responsive Element Binding Protein 1.Journal of cosmetic dermatology · 2025Article
- Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties.Molecules (Basel, Switzerland) · 2025Article
- Efficacy, safety, and cost-effectiveness of glycolic acid vs. azelaic acid in melasma.Journal of family medicine and primary care · 2025Article
- A real-world study to observe the efficacy and safety of Lutai Danshen Baishao Granules for improving melasma.Medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melasma is a chronic hyperpigmentation skin disorder that is more common in the female gender. Although melasma is a multifactorial skin disorder, however, sun-exposure and genetic predisposition are considered as the main etiologic factors in melasma occurrence. Although numerous topical and systemic therapeutic agents and also non-pharmacologic procedural treatments have been considered in melasma management, however, the commonly available therapeutic options have several limitations including the lack of sufficient clinical effectiveness, risk of relapse, and high rate of unwanted adverse drug reactions. Recruitment of nanotechnology for topical drug delivery in melasma management can lead to enhanced skin penetration, targeted drug delivery to the site of action, longer deposition at the targeted area, and limit systemic absorption and therefore systemic availability and adverse drug reactions. In the current review, first of all, the etiology, pathophysiology, and severity classification of melasma have been considered. Then, various pharmacologic and procedural therapeutic options in melasma treatment have been discussed. Afterward, the usage of various types of nanoparticles for the purpose of topical drug delivery for melasma management was considered. In the end, numerous clinical studies and controlled clinical trials on the assessment of the effectiveness of these novel topical formulations in melasma management are summarized.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.